The public offering was led by Perceptive Advisors and Nantahala Capital, with participation from other new institutional biotech investors. Company CEO George Magrath and board chairman Cam Gallagher ...

Opus Genetics announces $20 million public offering and $1.5 million private placement for gene therapy development and operations. Opus Genetics, Inc., a clinical-stage biotechnology company ...

For companies seeking to raise capital without the complexities and costs of a public offering, Regulation D under the ...

On March 12, 2025, the SEC dropped a massive amount of changes to their Compliance and Disclosure Interpretations (CDI’s) ...

The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced it has entered into a securities ...

QXO, Inc. (NYSE: QXO) (the "Company" or "QXO") today announced that it has entered into purchase agreements with certain ...

Spire Global, Inc. (NYSE: SPIR) ("Spire" or "the Company"), a global provider of space-based data, analytics and space services, today announced that it has entered into a securities purchase ...

Warrants to be issued as part of the public offering and concurrent private placement could bring in up to $21.4 million of additional capital 30 days following the release of OPGx-BEST1 DUO-1001 ...